What is Pegasys used for?
Pegasys (peginterferon alfa-2a) treats chronic hepatitis C virus (HCV) infection in adults and children, often with ribavirin. It targets liver damage from HCV by boosting the immune response to clear the virus.[1]
How does it help the liver?
Pegasys reduces HCV viral load, preventing further liver scarring (fibrosis) or cirrhosis. It's injected weekly under the skin, with treatment lasting 24-48 weeks depending on genotype and response.[1][2]
Is it for other liver conditions?
Pegasys is also approved for chronic hepatitis B (CHB) in adults and children over 3 years, where it suppresses HBV to limit liver inflammation and progression to cancer. It's not for acute hepatitis or non-viral liver diseases like alcoholic liver disease.[1]
Common side effects on the liver?
Liver enzyme elevations occur in up to 25% of patients, sometimes leading to discontinuation. Monitor ALT/AST levels closely; rare cases of liver failure reported in those with cirrhosis.[2]
When was Pegasys approved and who makes it?
FDA approved in 2002 for HCV and later expanded for HBV. Manufactured by Genentech (Roche subsidiary).[1]
Alternatives for liver-targeted HCV or HBV treatment?
Direct-acting antivirals (DAAs) like Epclusa or Harvoni have largely replaced Pegasys for HCV due to higher cure rates (95%+) and fewer side effects. For HBV, tenofovir or entecavir are first-line oral options.[3]
[1]: FDA Label for Pegasys
[2]: Pegasys Prescribing Information
[3]: Hepatitis C Guidelines - AASLD